Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)
Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –
Halozyme Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Halozyme Therapeutics's pe ratio was 30.0× on Nov 11, 2026, against 15.0× a year earlier. Over the last 5 years it ranged from 12.4× to 38.6×, with a median of 19.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 30.0× | +15.8 |
| 2025 | Dec 31, 2025 | 14.2× | −1.7 |
| 2024 | Dec 31, 2024 | 15.8× | −3.9 |
| 2023 | Dec 29, 2023 | 19.8× | −18.4 |
| 2022 | Dec 30, 2022 | 38.2× | +23.8 |
| 2021 | Dec 31, 2021 | 14.4× | −252.5 |
| 2020 | Dec 31, 2020 | 266.9× | +266.9 |
| 2019 | Jan 31, 2019 | 0.0× | +0.0 |
| 2018 | Dec 31, 2018 | 0.0× | – |
See a number that looks wrong?